Navigation Links
Neurobiological Technologies Announces Appointment of William A. Fletcher as Acting CEO
Date:2/4/2009

EMERYVILLE, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced the appointment of William A. Fletcher as the Company's Acting Chief Executive Officer. Mr. Fletcher has been a director of NTI since February 2007. With the Acting CEO appointment, the board of directors has discontinued its previously announced search for a permanent, full-time president and chief executive officer.

Mr. Fletcher has been Chairman, Teva Pharmaceuticals North America since December 2004. Prior to that, he was President and Chief Executive Officer of Teva's North American activities from 1985 until the end of 2004. Mr. Fletcher served as Vice President, Sales and Marketing of the Pennsylvania-based Lemmon Company (1980 to 1983) and then as President (1983-1985) following the company's acquisition by Teva and WR Grace. Mr. Fletcher graduated in International Marketing from Woolwich Polytechnic, London (now Greenwich University) in 1969.

"Together with the rest of the board of directors, I am committed to determining the best direction for Neurobiological Technologies as we evaluate alternatives following the failure of our Viprinex(TM) program for stroke. I intend to lead this process in a disciplined and expeditious manner," stated Mr. Fletcher. "We are continuing to downsize the Company while critically assessing our obligations and commitments in order to determine the best value for our shareholders."

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The company recently terminated development of its most advanced product candidate, Viprinex(TM) (ancrod), which was studied in Phase 3 clinical trials for evaluation as a new drug to treat acute ischemic stroke. NTI has an early-stage development program for Alzheimer's disease and rights to receive payments on an approved drug for Alzheimer's disease and an investigational drug which has recently completed a Phase 3 trial for brain swelling.

NOTE: Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including risks relating to our terminated clinical trials and our continuing contractual commitments, and levels of future operations and expenditures, as well as other risks detailed from time to time in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release and we undertake no obligation to update these forward-looking statements.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Neurobiological Technologies Reports Second Quarter Financial Results
2. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
3. Neurobiological Technologies Announces Compliance With Nasdaq Listing Standards
4. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
5. Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ
6. Neurobiological Technologies Reports Going Concern Qualification
7. Dilon Technologies Slant15(TM) and LEHR Collimators Enhance Imaging Capabilities
8. Patient Safety Technologies Closes $2.55 Million Financing
9. Palomar Medical Technologies to Host Fourth Quarter and Year End 2008 Financial Results Conference Call and Webcast on February 5, 2009
10. Medusa Medical Technologies Announces Integration of Siren ePCR Suite(TM) with Philips HeartStart MRx Monitor/Defibrillator
11. Global Med Technologies(R) Licenses Multi-System Solution to One of Top Ten U.S. Donor Centers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... May 28, 2016 , ... "Color Grading media can be time consuming but ... their media," said Christina Austin - CEO of Pixel Film Studios. , With ... add stylish color grades to their footage. A LUT is a Lookup Table that ...
(Date:5/27/2016)... ... May 27, 2016 , ... Southland Log Homes , designer and manufacturer ... barn kits, which can be found on its website at SouthlandLogHomes.com. , The designs ... and they highlight the craftsmanship of timber post and beam construction. The result ...
(Date:5/27/2016)... ... May 27, 2016 , ... This campaign aims to provide a path ... a society can control and change. , As nearly 795,000 Americans suffering from a ... the United States. Plus, with an estimated 129,000 of these people dying from stroke, ...
(Date:5/27/2016)... NY (PRWEB) , ... May 27, 2016 , ... Aimed ... inspiring human interest stories, which come courtesy of leaders in the nursing and health ... industry, from leading advocates and associations—namely Abilene Christian University. , As the nursing ...
(Date:5/26/2016)... ... May 26, 2016 , ... W.S. Badger Co. ... been honored with a 2016 When Work Works Award for its use of effective ... the national When Work Works project administered by the Families and Work Institute (FWI) ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... Cirujanos holandeses han puesto en ... médicos a compartir sus mejores prácticas por el mundo ... médicos de Europa, África, Asia ... aplicación, que combina la transmisión en vivo con mensajería ... Educación   "Imagine un médico de Medicines ...
(Date:5/24/2016)... -- Diana Russell suffers from a form of rheumatoid arthritis ... This disease has put her in a wheelchair, and ... to leave her home.  Because of the size and ... wheelchair.  So if there is a family function, the ... to wait for the bus. Photo - ...
(Date:5/24/2016)... Celsion Corporation (NASDAQ: CLSN ... an update on its ongoing OVATION study, a ... the Company,s DNA-based immunotherapy, with the standard of ... advanced ovarian cancer who will undergo neoadjuvant chemotherapy ... IL-12 DNA plasmid vector formulated as a nanoparticle ...
Breaking Medicine Technology: